{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T08:00:25Z","timestamp":1780646425066,"version":"3.54.1"},"reference-count":103,"publisher":"Georg Thieme Verlag KG","issue":"05","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Thromb Haemost"],"published-print":{"date-parts":[[2013]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Anticoagulants are a mainstay of cardiovascular therapy, and parenteral anticoagulants have widespread use in cardiology, especially in acute situations. Parenteral anticoagulants include unfractionated heparin, low-molecular-weight heparins, the synthetic pentasaccharides fondaparinux, idraparinux and idrabiotaparinux, and parenteral direct thrombin inhibitors. The several shortcomings of unfractionated heparin and of low-molecular-weight heparins have prompted the development of the other newer agents. Here we review the mechanisms of action, pharmacological properties and side effects of parenteral anticoagulants used in the management of coronary heart disease treated with or without percutaneous coronary interventions, cardioversion for atrial fibrillation, and prosthetic heart valves and valve repair. Using an evidence-based approach, we describe the results of completed clinical trials, highlight ongoing research with currently available agents, and recommend therapeutic options for specific heart diseases.<\/jats:p>","DOI":"10.1160\/th12-06-0403","type":"journal-article","created":{"date-parts":[[2013,3,28]],"date-time":"2013-03-28T12:32:28Z","timestamp":1364473948000},"page":"769-786","source":"Crossref","is-referenced-by-count":34,"title":["Parenteral anticoagulants in heart disease: Current status and perspectives (Section II)"],"prefix":"10.1160","volume":"109","author":[{"given":"Steen","family":"Husted","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Wallentin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felicita","family":"Andreotti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harald","family":"Arnesen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fedor","family":"Bachmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin","family":"Baigent","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kurt","family":"Huber","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f8rgen","family":"Jespersen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steen","family":"Kristensen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory Y. H.","family":"Lip","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o","family":"Morais","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Rasmussen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agneta","family":"Siegbahn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Freek W. A.","family":"Verheugt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey I.","family":"Weitz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaele","family":"De Caterina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2017,11,22]]},"reference":[{"key":"10.1160\/TH12-06-0403-1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehr373"},{"key":"10.1160\/TH12-06-0403-2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehl492"},{"key":"10.1160\/TH12-06-0403-3","doi-asserted-by":"publisher","DOI":"10.1160\/TH12-10-0772"},{"key":"10.1160\/TH12-06-0403-4","first-page":"2719","volume":"21","author":"Camm","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1160\/TH12-06-0403-5","doi-asserted-by":"publisher","DOI":"10.1016\/S0049-3848(10)70147-X"},{"key":"10.1160\/TH12-06-0403-6","doi-asserted-by":"publisher","DOI":"10.1378\/chest.126.3_suppl.188S"},{"key":"10.1160\/TH12-06-0403-7","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1016\/S0021-9258(18)34900-7","volume":"257","author":"Tollefsen","year":"1982","journal-title":"J Biol Chem"},{"key":"10.1160\/TH12-06-0403-8","doi-asserted-by":"crossref","first-page":"26796","DOI":"10.1016\/S0021-9258(18)47089-5","volume":"269","author":"Barrow","year":"1994","journal-title":"J Biol Chem"},{"key":"10.1160\/TH12-06-0403-9","doi-asserted-by":"publisher","DOI":"10.1021\/bi0342923"},{"key":"10.1160\/TH12-06-0403-10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2003.10.019"},{"key":"10.1160\/TH12-06-0403-11","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.103.18.2310"},{"key":"10.1160\/TH12-06-0403-12","doi-asserted-by":"crossref","first-page":"2600","DOI":"10.1182\/blood.V81.10.2600.2600","volume":"81","author":"Rao","year":"1993","journal-title":"Blood"},{"key":"10.1160\/TH12-06-0403-13","first-page":"116","volume":"16","author":"Dawes","year":"1986","journal-title":"Haemostasis"},{"key":"10.1160\/TH12-06-0403-14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198610303151801"},{"key":"10.1160\/TH12-06-0403-15","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-119-9-199311010-00002"},{"key":"10.1160\/TH12-06-0403-16","doi-asserted-by":"publisher","DOI":"10.1378\/chest.11-2291"},{"key":"10.1160\/TH12-06-0403-17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197208172870703"},{"key":"10.1160\/TH12-06-0403-18","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.161.3.385"},{"key":"10.1160\/TH12-06-0403-19","doi-asserted-by":"publisher","DOI":"10.1378\/chest.11-2303"},{"key":"10.1160\/TH12-06-0403-20","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1160\/TH08-10-0659","volume":"101","author":"Chong","year":"2009","journal-title":"Thromb Haemost"},{"key":"10.1160\/TH12-06-0403-21","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2005.07.012"},{"key":"10.1160\/TH12-06-0403-22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp052967"},{"key":"10.1160\/TH12-06-0403-23","doi-asserted-by":"crossref","unstructured":"Weitz JI. Low-molecular-weight heparins. N Engl J Med 1997; 337: 688-699; correction 1997; 337: 567","DOI":"10.1056\/NEJM199709043371007"},{"key":"10.1160\/TH12-06-0403-24","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(00)00695-1"},{"key":"10.1160\/TH12-06-0403-25","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.98.4.294"},{"key":"10.1160\/TH12-06-0403-26","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-8703(03)00121-2"},{"key":"10.1160\/TH12-06-0403-27","doi-asserted-by":"publisher","DOI":"10.1159\/000186641"},{"key":"10.1160\/TH12-06-0403-28","doi-asserted-by":"publisher","DOI":"10.1067\/mhj.2002.120774"},{"key":"10.1160\/TH12-06-0403-29","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200326030-00005"},{"key":"10.1160\/TH12-06-0403-30","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199505183322003"},{"key":"10.1160\/TH12-06-0403-31","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1520-6661(200003\/04)9:2<122::AID-MFM7>3.0.CO;2-Q"},{"key":"10.1160\/TH12-06-0403-32","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1055\/s-0037-1612970","volume":"87","author":"Pettil\u00e4","year":"2002","journal-title":"Thromb Haemost"},{"key":"10.1160\/TH12-06-0403-33","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1159\/000073848","volume":"33","author":"Wawrzy\u0144ska","year":"2003","journal-title":"Pathophysiol Haemost Thromb"},{"key":"10.1160\/TH12-06-0403-34","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2004.03.004"},{"key":"10.1160\/TH12-06-0403-35","doi-asserted-by":"publisher","DOI":"10.2174\/187152510791170933"},{"key":"10.1160\/TH12-06-0403-36","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1160\/TH09-01-0063","volume":"102","author":"Petitou","year":"2009","journal-title":"Thromb Haemost"},{"key":"10.1160\/TH12-06-0403-37","doi-asserted-by":"publisher","DOI":"10.1046\/j.1538-7836.2003.00536.x"},{"key":"10.1160\/TH12-06-0403-38","doi-asserted-by":"publisher","DOI":"10.1016\/S0049-3848(02)00340-7"},{"key":"10.1160\/TH12-06-0403-39","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1160\/TH07-04-0252","volume":"99","author":"Lobo","year":"2008","journal-title":"Thromb Haemost"},{"key":"10.1160\/TH12-06-0403-40","doi-asserted-by":"publisher","DOI":"10.1002\/bjs.4809"},{"key":"10.1160\/TH12-06-0403-41","doi-asserted-by":"publisher","DOI":"10.1007\/s00223-002-2091-5"},{"key":"10.1160\/TH12-06-0403-42","doi-asserted-by":"crossref","first-page":"4197","DOI":"10.1182\/blood.V91.11.4197","volume":"91","author":"Herbert","year":"1998","journal-title":"Blood"},{"key":"10.1160\/TH12-06-0403-43","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1160\/TH09-08-0555","volume":"102","author":"Harenberg","year":"2009","journal-title":"Thromb Haemost"},{"key":"10.1160\/TH12-06-0403-44","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60168-3"},{"key":"10.1160\/TH12-06-0403-45","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)61505-5"},{"key":"10.1160\/TH12-06-0403-46","doi-asserted-by":"publisher","DOI":"10.1160\/TH10-07-0495"},{"key":"10.1160\/TH12-06-0403-47","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1160\/TH07-11-0693","volume":"99","author":"Warkentin","year":"2008","journal-title":"Thromb Haemost"},{"key":"10.1160\/TH12-06-0403-48","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehn416"},{"key":"10.1160\/TH12-06-0403-49","doi-asserted-by":"crossref","unstructured":"Steg PG, James SK, Atar D, et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2012 33: 2569-2619","DOI":"10.1093\/eurheartj\/ehs215"},{"key":"10.1160\/TH12-06-0403-50","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198810273191701"},{"key":"10.1160\/TH12-06-0403-51","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(90)91155-Y"},{"key":"10.1160\/TH12-06-0403-52","doi-asserted-by":"crossref","unstructured":"The RISC Group. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet 1990 336: 827-830","DOI":"10.1016\/0140-6736(90)92336-G"},{"key":"10.1160\/TH12-06-0403-53","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.89.1.81"},{"key":"10.1160\/TH12-06-0403-54","doi-asserted-by":"publisher","DOI":"10.1016\/0735-1097(94)90539-8"},{"key":"10.1160\/TH12-06-0403-55","doi-asserted-by":"publisher","DOI":"10.1016\/0735-1097(95)80001-W"},{"key":"10.1160\/TH12-06-0403-56","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1996.03540100055028"},{"key":"10.1160\/TH12-06-0403-57","doi-asserted-by":"crossref","unstructured":"Wallentin L, Ohlsson J, Swahn E. Low-molecular-weight heparin during instability in coronary artery disease: Fragmin during Instability in Coronary Artery Disease (FRISC) Study Group. Lancet 1996 347: 561-568","DOI":"10.1016\/S0140-6736(96)91270-2"},{"key":"10.1160\/TH12-06-0403-58","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)02324-2"},{"key":"10.1160\/TH12-06-0403-59","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(99)07350-X"},{"key":"10.1160\/TH12-06-0403-60","doi-asserted-by":"crossref","unstructured":"Camm AJ, Kirchhof P, Lip GYH, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010 31: 2369-2429","DOI":"10.1093\/eurheartj\/ehq278"},{"key":"10.1160\/TH12-06-0403-61","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.108.190748"},{"key":"10.1160\/TH12-06-0403-62","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehs109"},{"key":"10.1160\/TH12-06-0403-63","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2011.04445.x"},{"key":"10.1160\/TH12-06-0403-64","doi-asserted-by":"crossref","unstructured":"The Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 Investigators. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. Lancet 2001 358: 605-613","DOI":"10.1016\/S0140-6736(01)05775-0"},{"key":"10.1160\/TH12-06-0403-65","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60876-3"},{"key":"10.1160\/TH12-06-0403-66","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000081659.72985.A8"},{"key":"10.1160\/TH12-06-0403-67","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.051410"},{"key":"10.1160\/TH12-06-0403-68","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.105.573550"},{"key":"10.1160\/TH12-06-0403-69","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa060898"},{"key":"10.1160\/TH12-06-0403-70","doi-asserted-by":"crossref","unstructured":"Sleight P, Eikelboom JW, Bassand JP. Enoxaparin versus unfractionated heparin in ST-elevation myocardial infarction. N Engl J Med 2006; 354: 2830-2831; author reply 2831-2832","DOI":"10.1056\/NEJMc061197"},{"key":"10.1160\/TH12-06-0403-71","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.96.1.61"},{"key":"10.1160\/TH12-06-0403-72","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.100.15.1602"},{"key":"10.1160\/TH12-06-0403-73","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199708143370702"},{"key":"10.1160\/TH12-06-0403-74","doi-asserted-by":"crossref","unstructured":"Antman EM, McCabe CH, Gurfinkel EP, et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina\/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial. Circulation 1999 100: 1593-1601","DOI":"10.1161\/01.CIR.100.15.1593"},{"key":"10.1160\/TH12-06-0403-75","doi-asserted-by":"crossref","unstructured":"The FRAX.I.S. Study Group. Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q wave myocardial infarction: FRAX.I.S. (FRAxiparine in Ischaemic Syndrome). Eur Heart J 1999 20: 1553-1562","DOI":"10.1053\/euhj.1999.1879"},{"key":"10.1160\/TH12-06-0403-76","doi-asserted-by":"crossref","unstructured":"Goodman SG, Fitchett D, Armstrong PW, et al. Randomized evaluation of the safety and efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb\/IIIa inhibitor eptifibatide. Circulation 2003 107: 238-244","DOI":"10.1161\/01.CIR.0000050144.67910.13"},{"key":"10.1160\/TH12-06-0403-77","doi-asserted-by":"publisher","DOI":"10.1001\/jama.292.1.45"},{"key":"10.1160\/TH12-06-0403-78","doi-asserted-by":"publisher","DOI":"10.1001\/jama.292.1.55"},{"key":"10.1160\/TH12-06-0403-79","doi-asserted-by":"publisher","DOI":"10.1067\/mhj.2002.126115"},{"key":"10.1160\/TH12-06-0403-80","doi-asserted-by":"publisher","DOI":"10.1001\/jama.292.1.89"},{"key":"10.1160\/TH12-06-0403-81","doi-asserted-by":"crossref","unstructured":"Kolh P, Wijns W, Danchin N, et al. Guidelines on myocardial revascularisation. Eur J Cardiothorac Surg 2010; 38 (Suppl 1:) S1-S52","DOI":"10.1016\/j.ejcts.2010.08.019"},{"key":"10.1160\/TH12-06-0403-82","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.103.5.658"},{"key":"10.1160\/TH12-06-0403-83","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-8703(03)00165-0"},{"key":"10.1160\/TH12-06-0403-84","doi-asserted-by":"crossref","unstructured":"Kereiakes DJ, Kleiman NS, Fry E, et al. Dalteparin in combination with abciximab during percutaneous coronary intervention. Am Heart J 2001 141: 348-352","DOI":"10.1067\/mhj.2001.113217"},{"key":"10.1160\/TH12-06-0403-85","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCINTERVENTIONS.109.884478"},{"key":"10.1160\/TH12-06-0403-86","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehq330"},{"key":"10.1160\/TH12-06-0403-87","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa052711"},{"key":"10.1160\/TH12-06-0403-88","doi-asserted-by":"crossref","unstructured":"Mehta SR, Steg PG, Granger CB, et al. Randomized, blinded trial comparing fondaparinux with unfractionated heparin in patients undergoing contemporary percutaneous coronary intervention: Arixtra Study in Percutaneous Coronary Intervention: a Randomized Evaluation (ASPIRE) Pilot Trial. Circulation 2005 111: 1390-1397","DOI":"10.1161\/01.CIR.0000158485.70761.67"},{"key":"10.1160\/TH12-06-0403-89","doi-asserted-by":"publisher","DOI":"10.1001\/jama.295.13.joc60038"},{"key":"10.1160\/TH12-06-0403-90","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa055443"},{"key":"10.1160\/TH12-06-0403-91","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2004.02.051"},{"key":"10.1160\/TH12-06-0403-92","doi-asserted-by":"publisher","DOI":"10.1053\/euhj.2001.2777"},{"key":"10.1160\/TH12-06-0403-93","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1055\/s-0037-1614445","volume":"81","author":"Vuillemenot","year":"1999","journal-title":"Thromb Haemost"},{"key":"10.1160\/TH12-06-0403-94","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(06)68845-4"},{"key":"10.1160\/TH12-06-0403-95","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2010.1320"},{"key":"10.1160\/TH12-06-0403-96","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehr236"},{"key":"10.1160\/TH12-06-0403-97","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0708191"},{"key":"10.1160\/TH12-06-0403-98","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60764-2"},{"key":"10.1160\/TH12-06-0403-99","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000120509.64740.DC"},{"key":"10.1160\/TH12-06-0403-100","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa062437"},{"key":"10.1160\/TH12-06-0403-101","doi-asserted-by":"publisher","DOI":"10.2217\/14796678.3.4.345"},{"key":"10.1160\/TH12-06-0403-102","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1109596"},{"key":"10.1160\/TH12-06-0403-103","doi-asserted-by":"publisher","DOI":"10.1002\/ccd.20352"}],"container-title":["Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1160\/TH12-06-0403.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,12]],"date-time":"2022-02-12T16:18:28Z","timestamp":1644682708000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1160\/TH12-06-0403"}},"subtitle":["Position Paper of the ESC Working Group on Thrombosis \u2013 Task Force on Anticoagulants in Heart Disease"],"short-title":[],"issued":{"date-parts":[[2013]]},"references-count":103,"journal-issue":{"issue":"05","published-online":{"date-parts":[[2017,11,22]]},"published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1160\/th12-06-0403","relation":{},"ISSN":["0340-6245","2567-689X"],"issn-type":[{"value":"0340-6245","type":"print"},{"value":"2567-689X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013]]}}}